Tianjin TEDA Biomedical redesignates Xia Alan Zhe as non-executive director

• Tianjin TEDA Biomedical Engineering said executive director Xia Alan Zhe applied to be redesignated as non-executive director, citing restrictions tied to his asset-management responsible officer license.
• Board proposed amending articles to allow four non-executive directors, enabling Xia’s redesignation while keeping board size at nine.
• Redesignation will take effect only after shareholder approval at annual general meeting, with Xia not taking part in day-to-day management until then.
• Xia was appointed executive director on Dec. 31, 2025; he is managing director and responsible officer at INV Advisory in Hong Kong, with prior senior roles at UBS Global Asset Management (China) and SDIC RE Asset Management.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin TEDA Biomedical Engineering Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260430-12140600), on April 30, 2026, and is solely responsible for the information contained therein.